found on chromosome 13q34. Heterogeneous mutations have been described in FVII deficient patients. Treatment There are several treatments available for factor VII deficiency; they all replace deficient FVII. Recombinant FVIIa concentrate (rFVIIa) is a recombinant treatment that is highly effective and has no risk of fluid overload or viral disease. It may be the optimal therapy. Plasma derived Factor VII concentrate (pdFVII) : This treatment is suitable for surgery but can lead to thrombosis. It is virus attenuated. Prothrombin complex concentrate (PCC) containing factor VII: this treatment is suitable for surgery, but has a risk of thrombosis. It is virus attenuated. Fresh frozen plasma (FFP): This is relatively inexpensive and readily available. While effective this treatment carries a risk of blood-borne viruses and fluid overload. History The condition was first described by Dr. B. Alexander, R. Goldstein, G. Landwehr G, and CD. Cook in 1951. References External links Bleeding Coagulopathies